By Elizabeth S. Eaton | Sep 6, 2017 | 11:22 PM GMT
Merck & Co. Inc. (NYSE:MRK) is acquiring immuno-oncology company Rigontec GmbH (Munich, Germany). Rigontec will receive €115 million ($136.8 million) in cash up front and is eligible for up to €349 million ($415.2
Read the full 337 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury